ReviewOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2018
The effect of icariin on bone metabolism and its potential clinical application.
Review in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 128 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
128 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mechanisms and traditional Chinese medicine therapeutics for primary osteoporosis: an integrated perspective.Frontiers in endocrinology · 2025Pooled it
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study of Jianyao Migu Granules in the Treatment of Osteopenic Low Back Pain.Journal of pain research · 2022Trial
- Bioactive Natural Compounds: A Review of Their Integration into Bone Tissue Engineering Scaffolds.Annals of biomedical engineering · 2026Review
- Icariin: Multi-target natural products for the multi-stage prevention and treatment of breast cancer (Review).Molecular and clinical oncology · 2026Review
- Icariin Modulates the Reproductive-Immune Axis: Molecular Insights and Therapeutic Potential.Current issues in molecular biology · 2026Review
- miR-376c-3p mediates icariin's anti-osteoclastogenic effect by targeting Mmp3.Journal of orthopaedic surgery and research · 2026Article
- Traditional Chinese medicine regulating Wnt/β-catenin and OPG/RANKL/RANK pathways in osteoporosis: a narrative review based on bone coupling and pathological subtype differences.Frontiers in medicine · 2026Review
- Icariin: from preclinical promise to clinical reality-a critical evidence-based assessment.Frontiers in pharmacology · 2026Review
- The Mechanism of Icariin in Regulating BMSCs for Treating Osteoporosis: A Review.Endocrine, metabolic & immune disorders drug targets · 2026Review
- Icariin alleviates triptolide-induced testicular vacuolization via modulating germline ferroptosis and blood-testis barrier integrity.Frontiers in cell and developmental biology · 2026Article
- Effectiveness and Current Status of Icariin in the Treatment of Rotator Cuff Injury Associated with Osteoporosis.Current protein & peptide science · 2026Review
- One-step strategy for fabricating icariin-encapsulated biomimetic Scaffold: Orchestrating immune, angiogenic, and osteogenic cascade for enhanced bone regeneration.Bioactive materials · 2025Article
- Enhancing Cellular Interactions Through Bioactivation and Local Nanomechanical Reinforcement in Nanodiamond-Loaded 3D-Printed Gellan Gum Scaffolds.Materials (Basel, Switzerland) · 2025Article
- Research Progress on Icariin Promoting Bone Injury Repair and Regeneration.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Exploring the molecular mechanism of icariin improving spinal cord injury through network pharmacology combined with experimental verification.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- EIF4A3 enhances the viability, invasion and osteogenic differentiation of BMSCs via the USP53/SMAD5 pathway.Scientific reports · 2025Article
- Icariin-loaded composite scaffold promotes osteogenic differentiation and bone regeneration.BMC musculoskeletal disorders · 2025Article
- Review
- Nrf2 Activation as a Therapeutic Target for Flavonoids in Aging-Related Osteoporosis.Nutrients · 2025Review
- Targeting microglia polarization with Chinese herb-derived natural compounds for neuroprotection in ischemic stroke.Frontiers in cell and developmental biology · 2025Review
68 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Osteoporosis is a bone disease characterized by reduced bone mass, which leads to increased risk of bone fractures, and poses a significant risk to public health, especially in the elderly population. The traditional Chinese medicinal herb Epimedii has been utilized for centuries to treat bone fracture and bone loss. Icariin is a prenylated flavonol glycoside isolated from Epimedium herb, and has been shown to be the main bioactive component. This review provides a comprehensive survey of previous studies on icariin, including its structure and function, effect on bone metabolism, and potential for clinical application. These studies show that icariin promotes bone formation by stimulating osteogenic differentiation of BMSCs (bone marrow-derived mesenchymal stem cells), while inhibiting osteoclastogenic differentiation and the bone resorption activity of osteoclasts. Furthermore, icariin has been shown to be more potent than other flavonoid compounds in promoting osteogenic differentiation and maturation of osteoblasts. A 24-month randomized double-blind placebo-controlled clinical trial reported that icariin was effective in preventing postmenopausal osteoporosis with relatively low side effects. In conclusion, icariin may represent a class of flavonoids with bone-promoting activity, which could be used as potential treatment of postmenopausal osteoporosis.
Indexed as
Identifiers
29110063What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.